



CyGenica

Making cancer drugs safer and better

Area	Treatment
Headquarter	Ireland
Countries of operation	Ireland, India
Founding year	2017
Status	Prototype/MVP


Summary

Cancer drugs are toxic in high doses and useless in small ones. Our USG technology delivers drugs directly into the living cell striking perfect dosage. We take cancer from mortal to manageable radically improving the quality of life of cancer patients. CyGenica's USG is a proprietary engineered molecule that works just like a molecular drill: it can bore into the cell and deliver drugs into it without causing any harm to the cell solving the most crucial issue of intracellular delivery and lowering dosage by even 90%. USG is to the cell what a USB is to any computer. It's a system that allows safe transferring of (biological) information and thus its applications are not limited to oncology but expand also into Car-T applications & CRISPR cas9 gene editing toolbox as a key enabler.

Incubator programme	N/A
Approvals	N/A
Awards	N/A
Patents	N/A
Revenue (last yr)	N/A
Funds raised	\$320k SOSV Ireland \$220k BPCL India \$100k BIRAC India
Currently raising:	€1million

USE OF FUNDS

■ R&D ■ Patent protection ■ Marketing and administration ■ Salaries



Interested? Get in touch

✉ greg@clab.ventures
www.cygenica.com

